Efemoral Medical Raises $4.9M in Series A1 Funding

Efemoral Medical, a Los Altos, CA-based developer of superior interventional bioresorbable therapies, raised $4.9M in Series A1 funding.

The backers have been current traders, in addition to an skilled cohort of recent traders.

The firm intends to make use of the funds to assist rising enrollment in its ongoing first-in-human trial, EFEMORAL I.

Led by Christopher Haig, CEO, and Lewis B. Schwartz, MD, CMO, Efemoral Medical supplies bioresorbable options. The Efemoral Vascular Scaffold System (EVSS) with FlexStep Technology affords a brand new method to treating peripheral arterial illness (PAD) by addressing the precise anatomical challenges and sophisticated biomechanics of sufferers with athero-occlusive illness in the leg. Through the usage of inter-scaffold areas, the patented FlexStep Technology combines flexibility with assist to accommodate tortuosity and skeletal motion, whereas the balloon-expandable deployment system simply opens vessels and sustains wholesome blood circulate. The novel bioresorbable scaffold with long-term Sirolimus elution goals to revive regular vessel diameter on the time of the process, ship therapeutic advantages throughout all lesion lengths and morphologies, stop restenosis, and keep patency whereas leaving no everlasting implant behind.



Leave a Comment